[Federal Register Volume 87, Number 68 (Friday, April 8, 2022)] [Notices] [Pages 20875-20876] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2022-07563] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2022-P-0077] Determination That NASONEX (Mometasone Furoate) Nasal Spray, 0.05 Milligram/Spray (50 Microgram), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA, Agency, or we) has determined that NASONEX (mometasone furoate) nasal spray, 0.05 milligram (mg)/spray (50 microgram (mcg)), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements. FOR FURTHER INFORMATION CONTACT: Sungjoon Chi, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6216, Silver Spring, MD 20993-0002, 240- 402-9674, [email protected]. SUPPLEMENTARY INFORMATION: Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(j)) allows the submission of an ANDA to market a generic version of a previously approved drug product. To obtain approval, the ANDA applicant must show, among other things, that the generic drug product: (1) Has the same active ingredient(s), dosage form, route of administration, strength, conditions of use, and (with certain exceptions) labeling as the listed drug, which is a version of the drug that was previously approved, and (2) is bioequivalent to the listed drug. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA). [[Page 20876]] Section 505(j)(7) of the FD&C Act requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the ``Approved Drug Products With Therapeutic Equivalence Evaluations,'' which is known generally as the ``Orange Book.'' Under FDA regulations, drugs are removed from the list if the Agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162). A person may petition the Agency to determine, or the Agency may determine on its own initiative, whether a listed drug was withdrawn from sale for reasons of safety or effectiveness. This determination may be made at any time after the drug has been withdrawn from sale, but must be made prior to approving an ANDA that refers to the listed drug (Sec. 314.161 (21 CFR 314.161)). FDA may not approve an ANDA that does not refer to a listed drug. NASONEX (mometasone furoate) nasal spray, 0.05 mg/spray 50 (mcg), is the subject of NDA 020762, held by Organon LLC, and initially approved on October 1, 1997. NASONEX (mometasone furoate) nasal spray, 0.05 mg/spray 50 (mcg) is a corticosteroid indicated for:Treatment of nasal symptoms of allergic rhinitis in patients 2 years of age and older; treatment of nasal congestion associated with seasonal allergic rhinitis in patients 2 years of age or older; prophylaxis of seasonal allergic rhinitis in patients 12 years of age or older; and treatment of nasal polyps in patients 18 years of age or older. In a letter dated December 4, 2020, Merck Sharp and Dohme Corp., a subsidiary of Merck and Co., Inc., notified FDA that NASONEX (mometasone furoate) nasal spray, 0.05 mg/spray 50 (mcg) was being discontinued, and FDA moved the drug product to the ``Discontinued Drug Product List'' section of the Orange Book. Aurobindo Pharma Ltd. submitted a citizen petition dated January 14, 2022 (Docket No. FDA-2022-P-0077), under 21 CFR 10.30, requesting that the Agency determine whether NASONEX (mometasone furoate) nasal spray, 0.05 mg/spray 50 (mcg), was withdrawn from sale for reasons of safety or effectiveness. After considering the citizen petition and reviewing Agency records and based on the information we have at this time, FDA has determined under Sec. 314.161 that NASONEX (mometasone furoate) nasal spray, 0.05 mg/spray 50 (mcg) was not withdrawn for reasons of safety or effectiveness. The petitioner has identified no data or other information suggesting that NASONEX (mometasone furoate) nasal spray, 0.05 mg/spray 50 (mcg) was withdrawn for reasons of safety or effectiveness. We have carefully reviewed our files for records concerning the withdrawal of NASONEX (mometasone furoate) nasal spray, 0.05 mg/spray 50 (mcg) from sale. We have also independently evaluated relevant literature and data for possible postmarketing adverse events. We have found no information that would indicate that this drug product was withdrawn from sale for reasons of safety or effectiveness. Accordingly, the Agency will continue to list NASONEX (mometasone furoate) nasal spray, 0.05 mg/spray 50 (mcg), in the ``Discontinued Drug Product List'' section of the Orange Book. The ``Discontinued Drug Product List'' delineates, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness. FDA will not begin procedures to withdraw approval of approved ANDAs that refer to this drug product. Additional ANDAs for this drug product may also be approved by the Agency as long as they meet all other legal and regulatory requirements for the approval of ANDAs. If FDA determines that labeling for this drug product should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling. Dated: April 4, 2022. Lauren K. Roth, Associate Commissioner for Policy. [FR Doc. 2022-07563 Filed 4-7-22; 8:45 am] BILLING CODE 4164-01-P